All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @trezanderson_ on TikTok · 54s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @trezanderson_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00What they don't tell you about them shots then weight loss shots
  2. 0:06Is that you gonna get to a point
  3. 0:08You go in your closet
  4. 0:10And don't shit fit. Let me tell you something all my clothes to be all
  5. 0:16My clothes to be it ain't nothing that says
  6. 0:20No, everything is too big
  7. 0:25This the shot didn't come with a warning like hey, you'll catch up with you real quick
  8. 0:30Go ahead and start buying clothes and smaller sizes. No, I
  9. 0:35Didn't prepare for that. I
  10. 0:37Didn't think to be like, you know what?
  11. 0:39Let me keep all my old clothes that are giving away. Let me keep with them and elude it wait. I didn't think about that
  12. 0:46Now I'm gonna hit with big ass clothes
  13. 0:49Or nothing. It's just like I can't wait there, but a jack in the t-shirt

GLP-1 side effects went viral fast, but what's real?

La’Trez Anderson

TikTok creator

965.2K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide produce average weight reductions of 15 to 21% of body weight in clinical trials, with a significant portion of that loss occurring in the first three to five months of treatment. The rapid pace of weight loss described by @trezanderson_ is consistent with trial data from STEP 1 (Wilding et al., 2021) and SURMOUNT-1 (Jastreboff et al., 2022), where participants lost enough weight to require practical lifestyle adjustments that are rarely addressed in standard prescribing conversations. Patient preparation for GLP-1 therapy should include realistic timelines and practical planning, not only side-effect management.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For GLP-1 side effects went viral fast, but what's real?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

GLP-1 side effects went viral fast, but what's real? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "GLP-1 side effects went viral fast, but what's real?" from La'Trez Anderson. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide produce average weight reductions of 15 to 21% of body weight in clinical trials, with a significant portion of that loss occurring in the first three to five months of treatment.

The reason this review is not generic is the source wording and the canonical claim label "glp1 it happened so quick treztiwaun comedy blacktiktok." In this clip, the useful excerpt is: "What they don't tell you about them shots then weight loss shots Is that you gonna get to a point You go in your closet And don't shit fit." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

SURMOUNT-1 data (Jastreboff et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide produce average weight reductions of 15 to 21% of body weight in clinical trials, with a significant portion of that loss occurring in the first three to five months of treatment.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide produce average weight reductions of 15 to 21% of body weight in clinical trials, with a significant portion of that loss occurring in the first three to five months of treatment. The rapid pace of weight loss described by @trezanderson_ is consistent with trial data from STEP 1 (Wilding et al., 2021) and SURMOUNT-1 (Jastreboff et al., 2022), where participants lost enough weight to require practical lifestyle adjustments that are rarely addressed in standard prescribing conversations. Patient preparation for GLP-1 therapy should include realistic timelines and practical planning, not only side-effect management.
  • STEP 1 trial data (Wilding et al., 2021, NEJM): average 14.9% body weight loss on semaglutide 2.4mg over 68 weeks, with much of that loss occurring in the first 20 weeks.
  • SURMOUNT-1 data (Jastreboff et al., 2022, NEJM): tirzepatide users lost up to 20.9% of body weight on average, meaning a 200-pound person could lose roughly 40 pounds across treatment.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • STEP 1 trial data (Wilding et al., 2021, NEJM): average 14.9% body weight loss on semaglutide 2.4mg over 68 weeks, with much of that loss occurring in the first 20 weeks.
  • SURMOUNT-1 data (Jastreboff et al., 2022, NEJM): tirzepatide users lost up to 20.9% of body weight on average, meaning a 200-pound person could lose roughly 40 pounds across treatment.
  • Weight loss on GLP-1s is front-loaded: expect the most significant size changes in months one through four, not evenly distributed across the full treatment period.
  • STEP 4 trial (Rubino et al., 2021, JAMA): patients who stopped semaglutide regained about two-thirds of lost weight within 12 months, meaning any wardrobe changes may not be permanent if medication is discontinued.
  • Muscle loss during rapid weight loss is a documented risk; resistance training and protein intake of 1.2 to 1.6g per kilogram of body weight are recommended by the American Society for Metabolic and Bariatric Surgery to preserve lean mass.
  • Practical lifestyle preparation, including financial planning for clothing, is rarely included in GLP-1 prescribing conversations, a gap identified in obesity medicine literature as an area needing improvement.
  • Compounded versions of semaglutide and tirzepatide are not equivalent to FDA-approved brand-name medications and have not been tested in the same clinical trials referenced above.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @trezanderson_ actually say?

@trezanderson_ isn't making a medical claim here. He's venting about something genuinely practical: GLP-1 weight loss shots work fast enough that your wardrobe can't keep up. "Don't shit fit," he says, describing the moment he opened his closet and nothing worked anymore. His point is that nobody warned him the weight would come off quickly enough to strand him between sizes, with a closet full of clothes that are now "too big" and nothing to replace them.

This is a comedy video, not a health tutorial. But comedy can carry real information, and what he's describing, rapid enough weight loss to outpace wardrobe planning, is actually consistent with what clinical trial data shows for GLP-1 medications. The underlying observation is worth taking seriously even if the delivery is funny.

Does the science back this up?

Yes, and faster than most people expect. The clinical data on GLP-1 receptor agonists shows weight loss that can outpace a person's ability to plan for it, especially in the first few months. This is not a minor effect.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on tirzepatide lost an average of 20.9% of their body weight over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced an average 14.9% body weight reduction. To put that in concrete terms: a 200-pound person could lose 30 to 42 pounds. That is multiple clothing sizes. The weight loss is also front-loaded, with significant reduction happening in the first 12 to 20 weeks. So yes, "it happened so quick" is not an exaggeration. The trajectory he's describing lines up with what the trials actually show.

What did they get right?

Honestly, most of it. The speed of weight loss on GLP-1 medications is something that prescribers do not always prepare patients for, at least not practically. There is growing clinical literature on the psychological and social adjustments that accompany rapid body composition changes, including the financial cost of replacing clothing, which is a real barrier that lower-income patients face.

His frustration that "the shot didn't come with a warning" is a fair critique of how these medications are often presented. Informed consent conversations tend to focus on side effects like nausea, vomiting, and pancreatitis risk. They rarely include: budget for new clothes in smaller sizes over the next six months. A 2023 review by Rubino et al. in Nature Medicine noted that comprehensive support for GLP-1 patients should include lifestyle and practical planning, not just titration schedules. @trezanderson_ is identifying a real gap in patient preparation, just from a very funny angle.

What did they get wrong?

Nothing medically inaccurate appears in this video, because he isn't making medical claims. He's sharing a personal experience. The only thing worth flagging is what he leaves out, not what he gets wrong.

Weight loss on GLP-1 medications is not guaranteed to be linear or permanent. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that patients who discontinued semaglutide regained two-thirds of their lost weight within a year. So the wardrobe crisis he's describing could, in theory, reverse itself if the medication is stopped. That's not a reason to avoid these drugs. It is a reason to understand that the clothes you buy in smaller sizes may need to last only as long as you stay on the medication. That nuance is missing from the video, though again, it's a comedy clip, not a prescribing guide.

What should you actually know?

GLP-1 medications can produce meaningful, rapid weight loss, but rapid does not mean simple. Here's what the evidence says you should plan for that most people don't talk about.

  • Weight loss of 15 to 22% of body weight over 12 to 18 months is realistic on semaglutide or tirzepatide, based on current trial data. That is not a small change in how clothes fit.
  • Much of the loss happens early. You may drop one to two sizes in the first three to four months before the rate slows.
  • Muscle loss is a real concern during rapid weight loss. Resistance training and adequate protein intake matter. Without them, you may lose lean mass alongside fat, which affects body composition even at the same scale weight.
  • If you stop the medication, significant regain is likely without sustained behavioral changes. Plan accordingly.
  • Talk to your provider about realistic timelines before you start. Ask specifically: how fast might this happen, and what do I need to prepare for beyond the medication itself?

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

La’Trez Anderson · TikTok creator

965.2K views on this video

It happened so quick #treztiwaun #comedy #blacktiktok

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial data (wilding et al., 2021, nejm): average?

STEP 1 trial data (Wilding et al., 2021, NEJM): average 14.9% body weight loss on semaglutide 2.4mg over 68 weeks, with much of that loss occurring in the first 20 weeks.

What does the video say about surmount-1 data (jastreboff et al., 2022, nejm): tirzepatide users lost?

SURMOUNT-1 data (Jastreboff et al., 2022, NEJM): tirzepatide users lost up to 20.9% of body weight on average, meaning a 200-pound person could lose roughly 40 pounds across treatment.

What does the video say about weight loss on glp-1s?

Weight loss on GLP-1s is front-loaded: expect the most significant size changes in months one through four, not evenly distributed across the full treatment period.

What does the video say about step 4 trial (rubino et al., 2021, jama): patients who?

STEP 4 trial (Rubino et al., 2021, JAMA): patients who stopped semaglutide regained about two-thirds of lost weight within 12 months, meaning any wardrobe changes may not be permanent if medication is discontinued.

What does the video say about muscle loss during rapid weight loss?

Muscle loss during rapid weight loss is a documented risk; resistance training and protein intake of 1.2 to 1.6g per kilogram of body weight are recommended by the American Society for Metabolic and Bariatric Surgery to preserve lean mass.

What does the video say about practical lifestyle preparation, including financial planning for clothing,?

Practical lifestyle preparation, including financial planning for clothing, is rarely included in GLP-1 prescribing conversations, a gap identified in obesity medicine literature as an area needing improvement.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by La’Trez Anderson, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.